Description General description A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC50 = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC50 = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells. Note: aldehyde-based inhibitors are less cell-permeable than FMK-based inhibitors, so higher concentrations may be required for cell-based inhibition studies (e.g. 100 µM). A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC50 = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC50 = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells. Packaging 1 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: no Primary Target caspase-3, caspase-7 Product does not compete with ATP. Reversible: yes Target IC50: 3.2 nM and 22.6 nM, against caspases-3 and -7, respectively Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Sequence Ac-Asp-Asn-Leu-Asp-CHO Analysis Note Single main spot with additional trace spot by TLC Other Notes Yoshimori, A., et al. 2004. BMC Pharmacol.4, 7.